+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer/Tumor Profiling Market by Technology, Product Type, Application, End User - Global Forecast to 2030- Product Image
Cancer/Tumor Profiling Market by Technology, Product Type, Application, End User - Global Forecast to 2030- Product Image
Sale

Cancer/Tumor Profiling Market by Technology, Product Type, Application, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5592101
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Cancer/Tumor Profiling Market is rapidly evolving, driven by advances in molecular diagnostics and technology integration. Senior decision-makers are navigating a complex landscape defined by innovation, operational demands, and region-specific adoption patterns. This report presents strategic insights for leaders aiming to optimize positioning in a growing sector.

Market Snapshot: Cancer/Tumor Profiling Market

The Cancer/Tumor Profiling Market grew from USD 12.77 billion in 2024 to USD 15.29 billion in 2025. It is expected to continue growing at a CAGR of 18.86%, reaching USD 36.01 billion by 2030. Market momentum reflects the ongoing adoption of multi-omic approaches, genomic insight-driven therapies, and robust investment in precision oncology. Expanding reimbursement support, automation, and integrated workflows are sustaining this pace across diverse global regions. As regulatory landscapes and supply chains evolve, industry competitiveness will depend on data-driven agility and clinical validation.

Scope & Segmentation of the Cancer/Tumor Profiling Market

  • Technology: Conventional PCR, Digital PCR, Fluorescence In Situ Hybridization (FISH: Chromosome Enumeration Probes, Copy Number Variation, Fusion Gene Detection), Immunohistochemistry (Direct IHC, Indirect IHC, Tissue Microarray), Microarray (Comparative Genomic Hybridization, Expression Profiling, SNP Genotyping), Next Generation Sequencing (Targeted Sequencing: Amplicon Based, Hybrid Capture; Transcriptome, Exome, Genome Sequencing), Real-Time PCR (Dye Based, Probe Based)
  • Product Type: Consumables Reagents (Antibodies, PCR Reagents, Probes, Sequencing Reagents), Instruments (Fluorescence Microscopes, Mass Spectrometers, Microarray Scanners, PCR Instruments, Sequencers), Software & Services (Bioinformatics Software, Cloud Platforms, Consultation Services, Data Management Systems)
  • Application: Breast Cancer (Gene Expression Profiling, Genetic Mutation Detection, Proteomic Profiling, Receptor Profiling), Colorectal Cancer (Epigenetic Profiling, MSI Testing, Mutation Analysis), Lung Cancer (Minimal Residual Disease Monitoring, Molecular Susceptibility Testing, Therapy Selection), Prostate Cancer (Copy Number Variation Analysis, Fusion Detection, Gene Expression Analysis)
  • End User: Diagnostic Laboratories (Clinical Laboratories, Reference Laboratories), Hospitals & Clinics (Oncology Departments, Pathology Labs), Pharma & Biopharma Companies (Clinical Trial Units, Companion Diagnostic Services, Drug Development Divisions), Research & Academic Institutes (Biotech Research Centers, Government Research Institutes, University Research Labs)
  • Regions: Americas (United States: California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Leading Companies: Thermo Fisher Scientific Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, QIAGEN N.V., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Guardant Health, Inc., Natera, Inc., NeoGenomics, Inc.

Key Takeaways for Senior Decision-Makers

  • Integrated multi-omic technologies now underpin most tumor profiling workflows, offering deeper insights for personalized therapy selection and monitoring.
  • The shift toward modular diagnostic platforms strengthens adaptability, futureproofs infrastructure, and supports rapid incorporation of emerging biomarkers.
  • Collaboration between instrument providers, cloud service partners, and academic research accelerates innovation, validation, and clinical adoption.
  • Regional disparities, especially between developed and emerging markets, require tailored commercialization and distribution approaches to maximize growth and accessibility.
  • Growing reliance on artificial intelligence and advanced bioinformatics is enhancing data interpretation and informing clinical decision-making, enabling robust precision oncology strategies.
  • End users’ requirements—such as throughput, regulatory compliance, and data integration—differ significantly, reinforcing the need for configurable platform and service offerings across segments.

Tariff Impact Analysis

Recent adjustments to U.S. tariffs on critical reagents, instruments, and sequencing consumables have increased cost pressures for diagnostic and research organizations. Larger laboratories with established supply chain and procurement strategies demonstrated resilience, while smaller centers encountered delays and margin impacts. Industry adaptation has focused on diversified sourcing, progressive inventory controls, and partnerships to maintain operational continuity and mitigate supply risks.

Methodology & Data Sources

This research draws on a robust methodology combining expert interviews, analysis of regulatory documents, patent reviews, and quantitative triangulation with industry databases. Data harmonization and stringent normalization protocols ensured accurate and regionally representative findings.

Why This Report Matters

  • Provides decision-ready insights for executives driving tumor profiling adoption in clinical, research, and commercial settings.
  • Enables informed strategic planning by mapping competitive dynamics and regulatory trends across global regions and technology segments.
  • Supports investment and partnership decisions with granular segmentation, up-to-date methodology, and actionable opportunity identification.

Conclusion

Cancer/tumor profiling is advancing through technology convergence, regional expansion, and innovative collaborations. Informed action and targeted investment will help sector leaders capture latent value and address evolving clinical needs with precision.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cancer/Tumor Profiling Market, by Technology
8.1. Introduction
8.2. Conventional PCR
8.3. Digital PCR
8.4. FISH
8.4.1. Chromosome Enumeration Probes
8.4.2. Copy Number Variation
8.4.3. Fusion Gene Detection
8.5. IHC
8.5.1. Direct IHC
8.5.2. Indirect IHC
8.5.3. Tissue Microarray
8.6. Microarray
8.6.1. Comparative Genomic Hybridization
8.6.2. Expression Profiling
8.6.3. SNP Genotyping
8.7. Next Generation Sequencing
8.7.1. Targeted Sequencing
8.7.1.1. Amplicon Based
8.7.1.2. Hybrid Capture
8.7.2. Transcriptome Sequencing
8.7.3. Whole Exome Sequencing
8.7.4. Whole Genome Sequencing
8.8. Real Time PCR
8.8.1. Dye Based
8.8.2. Probe Based
9. Cancer/Tumor Profiling Market, by Product Type
9.1. Introduction
9.2. Consumables Reagents
9.2.1. Antibodies
9.2.2. PCR Reagents
9.2.3. Probes
9.2.4. Sequencing Reagents
9.3. Instruments
9.3.1. Fluorescence Microscopes
9.3.2. Mass Spectrometers
9.3.3. Microarray Scanners
9.3.4. PCR Instruments
9.3.5. Sequencers
9.4. Software & Services
9.4.1. Bioinformatics Software
9.4.2. Cloud Platforms
9.4.3. Consultation Services
9.4.4. Data Management Systems
10. Cancer/Tumor Profiling Market, by Application
10.1. Introduction
10.2. Breast Cancer
10.2.1. Gene Expression Profiling
10.2.2. Genetic Mutation Detection
10.2.3. Proteomic Profiling
10.2.4. Receptor Profiling
10.3. Colorectal Cancer
10.3.1. Epigenetic Profiling
10.3.2. MSI Testing
10.3.3. Mutation Analysis
10.4. Lung Cancer
10.4.1. Minimal Residual Disease Monitoring
10.4.2. Molecular Susceptibility Testing
10.4.3. Therapy Selection
10.5. Prostate Cancer
10.5.1. Copy Number Variation Analysis
10.5.2. Fusion Detection
10.5.3. Gene Expression Analysis
11. Cancer/Tumor Profiling Market, by End User
11.1. Introduction
11.2. Diagnostic Laboratories
11.2.1. Clinical Laboratories
11.2.2. Reference Laboratories
11.3. Hospitals Clinics
11.3.1. Oncology Departments
11.3.2. Pathology Labs
11.4. Pharma & Biopharma Companies
11.4.1. Clinical Trial Units
11.4.2. Companion Diagnostic Services
11.4.3. Drug Development Divisions
11.5. Research & Academic Institutes
11.5.1. Biotech Research Centers
11.5.2. Government Research Institutes
11.5.3. University Research Labs
12. Americas Cancer/Tumor Profiling Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Cancer/Tumor Profiling Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Cancer/Tumor Profiling Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Thermo Fisher Scientific Inc.
15.3.2. Illumina, Inc.
15.3.3. F. Hoffmann-La Roche Ltd
15.3.4. QIAGEN N.V.
15.3.5. Agilent Technologies, Inc.
15.3.6. Bio-Rad Laboratories, Inc.
15.3.7. PerkinElmer, Inc.
15.3.8. Guardant Health, Inc.
15.3.9. Natera, Inc.
15.3.10. NeoGenomics, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. CANCER/TUMOR PROFILING MARKET MULTI-CURRENCY
FIGURE 2. CANCER/TUMOR PROFILING MARKET MULTI-LANGUAGE
FIGURE 3. CANCER/TUMOR PROFILING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. CANCER/TUMOR PROFILING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. CANCER/TUMOR PROFILING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CANCER/TUMOR PROFILING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CHROMOSOME ENUMERATION PROBES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COPY NUMBER VARIATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FUSION GENE DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIRECT IHC, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INDIRECT IHC, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TISSUE MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY EXPRESSION PROFILING, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SNP GENOTYPING, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY AMPLICON BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HYBRID CAPTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DYE BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBE BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCING REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FLUORESCENCE MICROSCOPES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY SCANNERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOINFORMATICS SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLOUD PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSULTATION SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENETIC MUTATION DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEOMIC PROFILING, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RECEPTOR PROFILING, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY EPIGENETIC PROFILING, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MSI TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MUTATION ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MOLECULAR SUSCEPTIBILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COPY NUMBER VARIATION ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FUSION DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY ONCOLOGY DEPARTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PATHOLOGY LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL TRIAL UNITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COMPANION DIAGNOSTIC SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DRUG DEVELOPMENT DIVISIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 92. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, 2018-2030 (USD MILLION)
TABLE 93. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 94. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOTECH RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 95. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 96. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY UNIVERSITY RESEARCH LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 97. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 114. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 116. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, 2018-2030 (USD MILLION)
TABLE 117. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, 2018-2030 (USD MILLION)
TABLE 118. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 119. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 142. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 143. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2018-2030 (USD MILLION)
TABLE 144. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2018-2030 (USD MILLION)
TABLE 145. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 146. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 147. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2018-2030 (USD MILLION)
TABLE 148. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2018-2030 (USD MILLION)
TABLE 149. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 150. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2030 (USD MILLION)
TABLE 151. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 152. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 153. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 154. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 155. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 156. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 157. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 158. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 160. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, 2018-2030 (USD MILLION)
TABLE 161. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, 2018-2030 (USD MILLION)
TABLE 162. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 163. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 164. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2018-2030 (USD MILLION)
TABLE 165. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2018-2030 (USD MILLION)
TABLE 166. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 167. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 168. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2018-2030 (USD MILLION)
TABLE 169. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2018-2030 (USD MILLION)
TABLE 170. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 171. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2030 (USD MILLION)
TABLE 172. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 173. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 174. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 176. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 177. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 178. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 179. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 181. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, 2018-2030 (USD MILLION)
TABLE 182. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, 2018-2030 (USD MILLION)
TABLE 183. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 184. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 185. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2018-2030 (USD MILLION)
TABLE 186. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2018-2030 (USD MILLION)
TABLE 187. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 188. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 189. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2018-2030 (USD MILLION)
TABLE 190. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2018-2030 (USD MILLION)
TABLE 191. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 192. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2030 (USD MILLION)
TABLE 193. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 194. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 195. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 196. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 197. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 198. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 199. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 200. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 202. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, 2018-2030 (USD MILLION)
TABLE 203. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, 2018-2030 (USD MILLION)
TABLE 204. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 205. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 206. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2018-2030 (USD MILLION)
TABLE 207. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2018-2030 (USD MILLION)
TABLE 208. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 209. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 210. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2018-2030 (USD MILLION)
TABLE 211. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2018-2030 (USD MILLION)
TABLE 212. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 213. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2030 (USD MILLION)
TABLE 214. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 215. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 216. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 217. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 218. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 219. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 220. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 221. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 223. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, 2018-2030 (USD MILLION)
TABLE 224. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, 2018-2030 (USD MILLION)
TABLE 225. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2018-2030 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2018-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2018-2030 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2018-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, 2018-2030 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 248. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2018-2030 (USD MILLION)
TABLE 250. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2018-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 252. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2018-2030 (USD MILLION)
TABLE 254. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2018-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 256. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 258. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 260. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 262. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 264. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 266. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, 2018-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, 2018-2030 (USD MILLION)
TABLE 268. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 269. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 270. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2018-2030 (USD MILLION)
TABLE 271. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2018-2030 (USD MILLION)
TABLE 272. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 273. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 274. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2018-2030 (USD MILLION)
TABLE 275. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2018-2030 (USD MILLION)
TABLE 276. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 277. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2030 (USD MILLION)
TABLE 278. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 279. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 280. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 281. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 282. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 283. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 284. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 285. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 287. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, 2018-2030 (USD MILLION)
TABLE 288. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, 2018-2030 (USD MILLION)
TABLE 289. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 290. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 291. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2018-2030 (USD MILLION)
TABLE 292. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2018-2030 (USD MILLION)
TABLE 293. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 294. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 295. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2018-2030 (USD MILLION)
TABLE 296. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2018-2030 (USD MILLION)
TABLE 297. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 298. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2030 (USD MILLION)
TABLE 299. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 300. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 301. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 302. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 303. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 304. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 305. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 306. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 307. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 308. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, 2018-2030 (USD MILLION)
TABLE 309. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, 2018-2030 (USD MILLION)
TABLE 310. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 311. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 312. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2018-2030 (USD MILLION)
TABLE 313. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2018-2030 (USD MILLION)
TABLE 314. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 315. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 316. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2018-2030 (USD MILLION)
TABLE 317. RUSSIA CA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Cancer/Tumor Profiling market report include:
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • QIAGEN N.V.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • PerkinElmer, Inc.
  • Guardant Health, Inc.
  • Natera, Inc.
  • NeoGenomics, Inc.

Table Information

Report AttributeDetails
No. of Pages180
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 15.29 Billion
Forecasted Market Value ( USD ) by 2030 $ 36.01 Billion
Compound Annual Growth Rate18.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cancer/Tumor Profiling Market Report Size, Share, Trends, and Forecast by Cancer Type, Technology, Technique, Application, and Region, 2025-2033 - Product Image

Cancer/Tumor Profiling Market Report Size, Share, Trends, and Forecast by Cancer Type, Technology, Technique, Application, and Region, 2025-2033

  • Report
  • 136 Pages
  • Global
From
Tumor Profiling Market Size, Share & Trends Analysis Report By Technique (Genomics, Proteomics), By Technology, By Application (Personalized Cancer Medicine), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Tumor Profiling Market Size, Share & Trends Analysis Report By Technique (Genomics, Proteomics), By Technology, By Application (Personalized Cancer Medicine), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Cancer Tumor Profiling Market Report 2025 - Product Image

Cancer Tumor Profiling Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Cancer/Tumor Profiling Market Size and Forecasts 2020-2031: Global and Regional Share, Trends, and Growth Opportunity Analysis by Technology, Application, and End-user - Product Image

Cancer/Tumor Profiling Market Size and Forecasts 2020-2031: Global and Regional Share, Trends, and Growth Opportunity Analysis by Technology, Application, and End-user

  • Report
  • 117 Pages
  • Global
From
Cancer Diagnostics Market by Technology, Cancer Type, End User - Global Forecast to 2030 - Product Image

Cancer Diagnostics Market by Technology, Cancer Type, End User - Global Forecast to 2030

  • Report
  • 199 Pages
  • Global
From

About the Tumor Profiling Market

The Tumor Profiling market within the Diagnostics industry is a rapidly growing sector. It involves the use of advanced technologies such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) to analyze the genetic makeup of tumors. This helps to identify the specific mutations that are driving the tumor's growth, allowing for more targeted treatments. Tumor profiling can also be used to monitor the effectiveness of treatments and to detect recurrence of the tumor. The market is driven by the increasing prevalence of cancer, the growing demand for personalized medicine, and the development of new technologies. Additionally, the increasing availability of genomic data and the development of artificial intelligence (AI) and machine learning (ML) are expected to further drive the market. Some of the major companies in the Tumor Profiling market include Illumina, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, and Roche. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.